Communiqué de presse
Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma
EO2401 is a first-in-class OncoMimics™ peptide-based immunotherapy able to rapidly activate and significantly expand existing effector memory CD8+ T cells […]